Remifentanilo B. Braun

Remifentanilo B. Braun Uses, Dosage, Side Effects, Food Interaction and all others data.

Remifentanilo B. Braun (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanilo B. Braun is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.

Remifentanilo B. Braun is an opioid agonist with rapid onset and peak effect and ultra-short duration of action. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone. The analgesic effects of remifentanil are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other opioids. Remifentanilo B. Braun in humans has a rapid blood-brain equilibration half-time of 1 ± 1 minutes (mean ± SD) and a rapid onset of action.

Remifentanilo B. Braun
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Remifentanilo B. Braun
Availability	Prescription only
Generic	Remifentanil
Remifentanil Other Names	Remifentanil, Remifentanilo, Remifentanyl
Related Drugs	fentanyl, lidocaine, ketamine, hyoscyamine, propofol, glycopyrrolate
Type
Formula	C₂₀H₂₈N₂O₅
Weight	Average: 376.4467 Monoisotopic: 376.199822016
Protein binding	70% (bound to plasma proteins)
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	Portugal
Last Updated:	September 19, 2023 at 7:00 am

Uses

Remifentanilo B. Braun is an opioid analgesic used in anesthesia.

For use during the induction and maintenance of general anesthesia.

Remifentanilo B. Braun is also used to associated treatment for these conditions: Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation

How Remifentanilo B. Braun works

Remifentanilo B. Braun is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.

Food Interaction

Avoid alcohol. Ingesting alcohol may increase the sedative and CNS depressant effects of remifentanil.

Remifentanilo B. Braun Alcohol interaction

[Moderate] GENERALLY AVOID:

Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.

Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.

In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

Concomitant use of opioid analgesics with ethanol should be avoided.

Remifentanilo B. Braun Drug Interaction

Major: dantrolene, ondansetronModerate: alfentanil, diphenhydramine, meperidine, hydromorphone, chlorpheniramine / hydrocodone, midazolamUnknown: charcoal, epinephrine, amoxicillin / clavulanate, sulfamethoxazole / trimethoprim, heparin, furosemide, levothyroxine, atorvastatin, acetaminophen, vitamin a topical, bioflavonoids, sotalol

Remifentanilo B. Braun Disease Interaction

Major: prematurity, acute alcohol intoxication, gastrointestinal obstruction, hypotension, intracranial pressure, respiratory depressionModerate: adrenal insufficiency, hypothyroidism, seizure disorders, urinary retention, arrhythmias

Volume of Distribution

350 mL/kg
452 ± 144 mL/kg [neonates]
223 ± 30.6 mL/kg [adolescents]

Half Life

1-20 minutes

Clearance

40 mL/min/kg [young, healthy adults]

Elimination Route

Remifentanilo B. Braun is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.